A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes

Takagi, Tsutomu; Okura, Hiroyuki; Kobayashi, Yoshiki; Kataoka, Toru; Taguchi, Haruyuki; Toda, Iku; Tamita, Koichi; Yamamuro, Atsushi; Sakanoue, Yuji; Itō, Akira; Yanagi, Shiro; Shimeno, Kenji; Waseda, Katsuhisa; Yamasaki, Masao; Fitzgerald, Peter J.; Ikeno, Fumiaki; Honda, Yasuhiro; Yoshiyama, Minoru; Yoshikawa, Junichi; Investigators, Popps

doi:10.1016/j.jcin.2009.04.007

Cited by 59 publications

(45 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…receiving gliclazide/glimepiride. 262 Thiazolidinediones might be associated with lower restenosis rates after PCI with BMS, 263 but carry an increased risk of heart failure due to fluid retention. No trial has demonstrated that insulin or glucose-insulinpotassium (GIK) improves PCI outcome after STEMI.…”

Section: C -mentioning

confidence: 99%

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary

diabetes

Rydén

Grant

et al. 2014

Diabetes and Vascular Disease Research

175

View full text Add to dashboard Cite

Section: C -mentioning

confidence: 99%

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary

diabetes

Rydén

Grant

et al. 2014

Diabetes and Vascular Disease Research

175

View full text Add to dashboard Cite

“…Several studies performed in patients with diabetes have demonstrated a reduced incidence of ISR and TLR after BMS deployment associated with peroxisome proliferator-activated receptor agonist administration (96 -98). Accordingly, a recent study showed a lower ISR rate in patients with diabetes treated with DES when pioglitazone was added to standard treatment (96).…”

Section: Therapeutic Implicationsmentioning

confidence: 99%

The Evolving Role of Inflammatory Biomarkers in Risk Assessment After Stent Implantation

Niccoli

Montone

Ferrante

et al. 2010

Journal of the American College of Cardiology

105

View full text Add to dashboard Cite

The main adverse reactions to coronary stents are in-stent restenosis (ISR) and stent thrombosis. Along with procedural factors, individual susceptibility to these events plays an important role. In particular, inflammatory status, as assessed by C-reactive protein levels, predicts the risk of ISR after bare-metal stent implantation, although it does not predict the risk of stent thrombosis. Conversely, C-reactive protein levels fail to predict the risk of ISR after drug-eluting stent (DES) implantation, although they appear to predict the risk of stent thrombosis. Of note, DES have abated ISR rates occurring in the classical 1-year window, but new concern is emerging regarding late restenosis and thrombosis. The pathogenesis of these late events seems to be related to delayed healing and allergic reactions to polymers, a process in which eosinophils seem to play an important role by enhancing restenosis and thrombosis. The identification of high-risk individuals based on biomarker assessment may be important for the management of patients receiving stent implantation. In this report, we review the evolving role of inflammatory biomarkers in predicting the risk of ISR and stent thrombosis.

show abstract

“…Ponadto zaburzenia rytmu serca i powikłania niedokrwienne występowały rzadziej u pacjentów przyjmujących gliklazyd lub glimepiryd [370]. Stosowanie pochodnych tiazolidynodionu może się wiązać z niższym odsetkiem restenoz po PCI z wszczepieniem BMS [371], jednak niesie ze sobą zwiększone ryzyko niewydolności serca z powodu retencji płynu w nerkach (patrz również część 6.2.6).…”

Section: Rewaskularyzacja Mięśnia Sercowego a Leczenie Hipoglikemizująceunclassified

Wytyczne ESC dotyczące cukrzycy, stanu przedcukrzycowego i chorób układu sercowo- -naczyniowego opracowane we współpracy z EASD

Rydén

Grant

Anker³

et al. 2013

Kardiol Pol

View full text Add to dashboard Cite

A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes

Abstract: Pioglitazone treatment might suppress in-stent neointimal proliferation and reduce incidence of TLR after PCI in patients with T2DM.

Cited by 59 publications

References 52 publications

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary

The Evolving Role of Inflammatory Biomarkers in Risk Assessment After Stent Implantation

Wytyczne ESC dotyczące cukrzycy, stanu przedcukrzycowego i chorób układu sercowo- -naczyniowego opracowane we współpracy z EASD

Contact Info

Product

Resources

About